De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
The FDA has granted Orphan Drug designation to EXE-346 (ExeGi Pharma) for the prevention of disease relapse in pouchitis.
The True North study included patients with moderate to severe ulcerative colitis who had an inadequate response to prior treatment.
The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody designed to selectively inhibit α4β7 and αEβ7 integrins.
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.